

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

**FURTHER ANNOUNCEMENT ON
THE CONTINUING CONNECTED TRANSACTION UNDER
THE EXCLUSIVE PROMOTION SERVICES COOPERATION AGREEMENT**

Reference is made to the announcement of Simcere Pharmaceutical Group Limited (the “**Company**”) dated December 29, 2023 (the “**Announcement**”) in relation to, among others, the continuing connected transaction contemplated under the Exclusive Promotion Services Cooperation Agreement entered into between Jiangsu Simcere, an indirectly wholly-owned subsidiary of the Company, and Beijing Simcere Sanroad on December 29, 2023. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Company hereby announces that the shareholders of Beijing Simcere Sanroad has approved the transactions contemplated under the Exclusive Promotion Services Cooperation Agreement at a general meeting held on January 16, 2024. Therefore, the Exclusive Promotion Services Cooperation Agreement has come into effect from January 16, 2024.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, January 17, 2024

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; and Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.